Verrica Q4 2025: YCANTH net revenue up 130% to $15.3M; total revenue $35.6M

Verrica Pharmaceuticals Inc.

Q4 product revenue $3.7M vs $0.3M YoY; total revenue $35.6M in 2025, up from $7.6M in 2024.
YCANTH dispensed units up 99% to 51,296 in 2025; SG&A cut by over 40% to $35.2M.
Net loss $17.9M ($1.68/share) for full year 2025 vs $76.6M ($14.78/share) in 2024.
Company has no outstanding debt; cash runway extended into Q1 2027.
Phase 3 for common warts initiated; VP-315 advancing to Phase 3 for basal cell carcinoma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Verrica Pharmaceuticals Inc. reported Fourth Quarter and Full Year 2025 results: revenue $35.6 million.

Period: Fourth Quarter and Full Year 2025
Revenue: $35.6 million
Result: reported results

Exact text from the filing

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results – YCANTH ® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-101126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.